Home
Resources
Publications
Betahistine Hydrochloride in Méniére's Disease

Betahistine Hydrochloride in Méniére's Disease

I J Frew, G N Menon

Postgrad Med J. 1976 Aug;52(610):501-3.

PMID: 790351

Abstract:

A double-blind, placebo-controlled, cross-over clinical trial was performed to assess the effect of betahistine hydrochloride (Serc) in Ménière's disease. The diagnosis was based on paroxysmal attacks of rotational vertigo, with tinnitus, and a fluctuating sensori-neural deafness, together with the results of auditory and vestigular tests. Twenty-eight patients were admitted to the trial over 3 years. Twenty-two patients completed the trial. In total, they received betahistine 32 mg daily, for a period of 16 weeks, and placebo also for the same length of time, preceded in every case by a 4-week pre-treatment period. Daily symptom score cards were kept. There was a statistically significant improvement in favour of the drug with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom. No adverse reactions were observed.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP5579840	Betahistine hydrochloride		5579-84-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: